Evidence map›Paper›PMID 34685551›Full record

ArticleCells2021

Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction.

Cristina Prat-Vidal, Verónica Crisóstomo, Isabel Moscoso, Claudia Báez-Díaz, Virginia Blanco-Blázquez, Guadalupe Gómez-Mauricio, Guillermo Albericio, Susana Aguilar, María-Eugenia Fernández-Santos, Francisco Fernández-Avilés and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Recapitulating porcine cardiac developmentFrontiers in cell and developmental biology · 2023
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Cristina Prat-VidalICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Can Ruti Campus, Heart Institute (iCor), Germans Trias i Pujol University Hospital, 08916 Badalona, Spain.ORCID 0000-0002-5621-1101
Verónica CrisóstomoCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-1740-7029
Isabel MoscosoCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-6078-4666
Claudia Báez-DíazCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Virginia Blanco-BlázquezCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Guadalupe Gómez-MauricioJesús Usón Minimally Invasive Surgery Center, 10071 Cáceres, Spain.
Guillermo AlbericioImmunology and Oncology Department, National Center for Biotechnology, 28049 Madrid, Spain.
Susana AguilarImmunology and Oncology Department, National Center for Biotechnology, 28049 Madrid, Spain.
María-Eugenia Fernández-SantosCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-9229-0022
Francisco Fernández-AvilésCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-5501-5275
Francisco M Sánchez-MargalloCIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-2138-988X
Antoni Bayes-GenisICREC Research Program, Germans Trias i Pujol Health Science Research Institute, Can Ruti Campus, Heart Institute (iCor), Germans Trias i Pujol University Hospital, 08916 Badalona, Spain.
Antonio BernadImmunology and Oncology Department, National Center for Biotechnology, 28049 Madrid, Spain.
Instituto de Salud Carlos III · ESCentro Nacional de Biotecnología · ESCentro de Cirugía de Mínima Invasión Jesús Usón · ESUniversidad Complutense de Madrid · ESUniversidade de Santiago de Compostela · ESUniversitat Autònoma de Barcelona · ES

Funding

Comunidad Autónoma de Madrid S2017/BMD-3692Instituto de Salud Carlos III CB16/11/00403Instituto de Salud Carlos III RD16/0011/0037Instituto de Salud Carlos III RETICS-RTI2018-097604-B-I00; PIC18/00014 and PI20/00247Ministerio de Ciencia e Innovación RTI2018-097604-B-I00Sixth Framework Programme HEALTH-2009_242038Spanish Cell Therapy Network (TerCel) RD16/0011/0006
6 · The paper itself

Abstract

Human cardiac progenitor cells (hCPC) are considered a good candidate in cell therapy for ischemic heart disease, demonstrating capacity to improve functional recovery after myocardial infarction (MI), both in small and large preclinical animal models. However, improvements are required in terms of cell engraftment and efficacy. Based on previously published reports, insulin-growth factor 1 (IGF-1) and hepatocyte growth factor (HGF) have demonstrated substantial cardioprotective, repair and regeneration activities, so they are good candidates to be evaluated in large animal model of MI. We have validated porcine cardiac progenitor cells (pCPC) and lentiviral vectors to overexpress IGF-1 (co-expressing eGFP) and HGF (co-expressing mCherry). pCPC were transduced and IGF1-eGFP

Indexed as

AnimalsDisease Models, AnimalFemaleHepatocyte Growth FactorInsulin-Like Growth Factor IMyocardial InfarctionMyocytes, CardiacStem CellsSwineHepatocyte Growth FactorInsulin-Like Growth Factor Icardiac progenitor celldecellularized extracellular matrixHGFIGF-1lentiviral vectorsmyocardial infarctionporcine large animal model

Identifiers

PMID34685551
PMCPMC8534140
OpenAlexW3204839924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.